Abstract: This document provides methods and materials related to assessing and treating breast cancer patients. For example, methods and materials that involve assessing a breast cancer patient to determine whether the patient has (1) cancer cells that over express HER-2 polypeptides or comprise a HER-2 amplification and (2) at least an intermediate CYP2D6 metabolizer status are provided.

Abstract: Materials and methods for evaluating cellular response to therapeutic agents.

Abstract: This document provides methods and materials related to assessing the likely outcome for mammals (e.g., humans) with cancer (e.g., breast cancer). For example, methods and materials for using the ratio of HOXB13 polypeptide expression to IL-17BR polypeptide expression, CYP2D6 genotype, medication history, or combinations thereof to determine the likelihood of a breast cancer patient to experience breast cancer relapse or death are provided.

Abstract: This document provides methods and materials related to assessing the likely outcome for mammals (e.g., humans) with cancer (e.g., breast cancer). For example, methods and materials that involve assessing a breast cancer patient's cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) genotype to determine the likelihood of the beast cancer patient to experience breast cancer relapse or death are provided. Methods and materials that involve assessing the likelihood that a breast cancer patient being treated with tamoxifen will experience side effects such as hot flashes also are provided.

Abstract: A method is provided for inhibiting growth of cancer cells comprising contacting said cells with an effective growth-inhibiting amount of a compound of the formula (II): ##STR1## or a physiologically acceptable salt thereof, wherein A.sup.1 and A.sup.2 are individually L-amino acid residue selected from the group consisting of Ala, Pro, Gly, Glu, Leu, Lys, Phe, Ser, Vl, Ile, Arg, Tyr, Thr, Asp, Asn and Gly; R.sup.1 is C.sub.1 -C.sub.6 (alkyl) which is unsubstituted or is substituted with an aromatic substituent or one or more in-chain bivalent groups selected from the group consisting of --O--, --CO--, --S--, --NH--, --CONH--, CH.dbd.CH--, and --SO.sub.2 --; Y.sup.1 and Y.sup.2 are each H, or taken together form a moiety derived from a dihydroxy compound, and R.sup.1 is H or an N-terminal protecting group.

Abstract: A method is provided for inhibiting growth of cancer cells comprising contacting said cells with an effective growth-inhibiting amount of a compound of the formula (II): ##STR1## or a physiologically acceptable salt thereof, wherein A.sup.1 and A.sup.2 are individually L-amino acid residues selected from the group consisting of Ala, Pro, Gly, Glu, Leu, Lys, Phe, Ser, Val, Ile, Arg, Tyr, Thr, Asp, Asn and Gly; R.sup.1 is C.sub.1 -C.sub.6 (alkyl) which is unsubstituted or is substituted with an aromatic substituent or one or more in-chain bivalent groups selected from the group consisting of --O--, --CO--, --S--, --NH--, --CONH--, CH.dbd.CH--, and --SO.sub.2 --; Y.sup.1 and Y.sup.2 are each H, or taken together from a moiety derived from a dihydroxy compound, and R.sup.1 is H or an N-terminal protecting group.

Abstract: A method is provided for reducing the side effects of chemotherapy with hexamethylmelamine (HMM) comprising intravelously administering a stabilized solution of HMM in an aqueous lipid dispersion, so that the central nervous system toxicity associated with oral HMM administration is reduced or eliminated.

Abstract: A method of inhibiting protease activity, growth, and colony formation in mammalian tumor cells by boronic acid analogs of amino acids, dipeptides and tripeptides. A method of coupling a boronic acid analog of an amino acid to other N-protected amino acids or N-protected dipeptides and compositions formed from the coupled products.